Vaxcyte, Inc. - PCVX STOCK NEWS

Vaxcyte, Inc. (Nasdaq: PCVX) announced the ongoing Phase 2 study of VAX-24 in healthy infants advanced to the second and final stage of the study, dosing the first new participants in July 2023. The company's lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate, demonstrated robust opsonophagocytic activity (OPA) immune responses across all 24 serotypes in adults aged 65 and older. The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied. Additionally, Vaxcyte completed a successful $575 million follow-on financing and published new VAX-GI preclinical data, receiving NIH grants. The company's cash, cash equivalents, and investments were $1.4 billion as of June 30, 2023, including net proceeds of $545.3 million from April's public offering.

Vaxcyte, Inc. to participate in a fireside chat at Jefferies Healthcare Conference

Vaxcyte announces positive results from Phase 2 study of VAX-24 in adults aged 65 and older, confirms clinical potential of lead vaccine candidate. Full safety data shows similar results to PCV20. Dosed first participants in infant Phase 2 study. $949.9 million in cash as of March 31, 2023.

Vaxcyte, Inc. (Nasdaq: PCVX) successfully closed its public offering of 13,030,000 shares of common stock at a price of $41.00 each, along with pre-funded warrants for 1,000,000 shares at $40.999 per share. This offering raised approximately $575 million in gross proceeds before expenses. The underwriting team, including BofA Securities and Jefferies, fully exercised an option for an additional 1,830,000 shares. These funds will support Vaxcyte's mission in developing innovative vaccines for bacterial diseases, including its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease. Vaxcyte utilizes a unique cell-free protein synthesis platform to enhance vaccine production efficiency.

Vaxcyte, Inc. (Nasdaq: PCVX) has announced a public offering of 11,200,000 shares of common stock and pre-funded warrants for approximately $500 million in gross proceeds. The common stock is priced at $41.00 per share, while pre-funded warrants are priced at $40.999 each, with an exercise price of $0.001. The offering is set to close on April 21, 2023, subject to customary conditions. The underwriters have an option to purchase up to an additional 1,830,000 shares. This capital raise aims to support Vaxcyte's ongoing development of innovative vaccines, including its lead candidate, VAX-24, targeting invasive pneumococcal disease. Vaxcyte's technology leverages advanced synthetic techniques to enhance vaccine efficacy.

Vaxcyte, Inc. (Nasdaq: PCVX) has initiated an underwritten public offering of its common stock and pre-funded warrants, seeking to raise capital to support its innovative vaccine initiatives. The offering will include an option for underwriters to buy an additional 15% of shares. The financial details of the offering are not yet disclosed, and the completion will depend on market conditions. BofA Securities, Jefferies, SVB Securities, Evercore ISI, and Guggenheim Securities are the joint book-running managers for this offering. The company has a robust pipeline focusing on vaccines to combat bacterial diseases, including its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine. This offering is designed to further strengthen Vaxcyte’s position in the vaccine market.

Vaxcyte, Inc. (PCVX) announced positive results from the VAX-24 Phase 2 study in adults aged 65 and older, confirming robust opsonophagocytic activity (OPA) immune responses across all 24 serotypes. The VAX-24 2.2mcg dose met non-inferiority criteria for 18 of 20 serotypes common with Prevnar 20 and demonstrated superior responses for four additional serotypes. Six-month safety data indicated similar safety and tolerability results compared to Prevnar 20. Vaxcyte plans to advance VAX-24 to a Phase 3 study, with topline data expected in 2025. The data supports VAX-24's potential as a best-in-class pneumococcal conjugate vaccine (PCV), aiming to reduce the incidence of invasive pneumococcal disease (IPD) among adults.